News | December 19, 2024
Vittoria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of VIPER-101
Read More
Press Release | December 11, 2024
Cyrus Biotechnology Announces Potent in vivo Redosability of an Engineered IdeS Protease for IgG-driven Autoimmune Disease, Demonstrating No Anti-drug Antibodies
Read More
News | December 9, 2024
Vittoria Biotherapeutics Presents Positive Preclinical Data at 66th Annual ASH Meeting Supporting its Novel Approach to Engineered CAR-T Cell Therapies
Read More
Press Release | November 13, 2024
TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development
Read More
